Advertisement

2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
Published:January 28, 2019DOI:https://doi.org/10.1016/j.hrthm.2019.01.024
      Glenn N. Levine, MD, FACC, FAHA, Chair

      Keywords

      To read this article in full you will need to make a payment
      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      Preamble

        • Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (U.S.)
        Clinical Practice Guidelines We Can Trust.
        National Academies Press, Washington, DC2011
        • Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (U.S.)
        Finding What Works in Health Care: Standards for Systematic Reviews.
        National Academies Press, Washington, DC2011
        • Anderson J.L.
        • Heidenreich P.A.
        • Barnett P.G.
        • et al.
        ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: 2304-2322
      1. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association. 2010. Available at: http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf and http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf. Accessed October 31, 2018.

        • Halperin J.L.
        • Levine G.N.
        • Al-Khatib S.M.
        • et al.
        Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        J Am Coll Cardiol. 2016; 67: 1572-1574
        • Jacobs A.K.
        • Anderson J.L.
        • Halperin J.L.
        The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 64: 1373-1384
        • Jacobs A.K.
        • Kushner F.G.
        • Ettinger S.M.
        • et al.
        ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2013; 61: 213-265
        • Arnett D.K.
        • Goodman R.A.
        • Halperin J.L.
        • et al.
        AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and US Department of Health and Human Services.
        J Am Coll Cardiol. 2014; 64: 1851-1856
        • January C.T.
        • Wann L.S.
        • Alpert J.S.
        • et al.
        2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
        J Am Coll Cardiol. 2014; 64: e1-e76
      1. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association. 2010. Available at: http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf and http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf. Accessed October 31, 2018.

        • Halperin J.L.
        • Levine G.N.
        • Al-Khatib S.M.
        • et al.
        Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        J Am Coll Cardiol. 2016; 67: 1572-1574
        • Jacobs A.K.
        • Kushner F.G.
        • Ettinger S.M.
        • et al.
        ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2013; 61: 213-265
        • Di Biase L.
        Use of direct oral anticoagulants in patients with atrial fibrillation and valvular heart lesions.
        J Am Heart Assoc. 2016; 5: e002776
        • Ezekowitz M.D.
        • Nagarakanti R.
        • Noack H.
        • et al.
        Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).
        Circulation. 2016; 134: 589-598
        • Pan K.-L.
        • Singer D.E.
        • Ovbiagele B.
        • et al.
        Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis.
        J Am Heart Assoc. 2017; 6: e005835
        • Floyd C.N.
        • Ferro A.
        Indications for anticoagulant and antiplatelet combined therapy.
        BMJ. 2017; 359: j3782
        • Lip G.Y.H.
        • Nieuwlaat R.
        • Pisters R.
        • et al.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation.
        Chest. 2010; 137: 263-272
        • Olesen J.B.
        • Torp-Pedersen C.
        • Hansen M.L.
        • et al.
        The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
        Thromb Haemost. 2012; 107: 1172-1179
        • Mason P.K.
        • Lake D.E.
        • DiMarco J.P.
        • et al.
        Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation.
        Am J Med. 2012; 125 (e1-6): 603
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • et al.
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Patel M.R.
        • Mahaffey K.W.
        • Garg J.
        • et al.
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Granger C.B.
        • Alexander J.H.
        • McMurray J.J.V.
        • et al.
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Giugliano R.P.
        • Ruff C.T.
        • Braunwald E.
        • et al.
        Edoxaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2013; 369: 2093-2104
        • Matchar D.B.
        • Jacobson A.
        • Dolor R.
        • et al.
        Effect of home testing of international normalized ratio on clinical events.
        N Engl J Med. 2010; 363: 1608-1620
        • Ezekowitz M.D.
        • James K.E.
        • Radford M.J.
        • et al.
        Initiating and maintaining patients on warfarin anticoagulation: the importance of monitoring.
        J Cardiovasc Pharmacol Ther. 1999; 4: 3-8
        • Hirsh J.
        • Fuster V.
        Guide to anticoagulant therapy. Part 2: oral anticoagulants. American Heart Association.
        Circulation. 1994; 89: 1469-1480
        • Cannegieter S.C.
        • Rosendaal F.R.
        • Wintzen A.R.
        • et al.
        Optimal oral anticoagulant therapy in patients with mechanical heart valves.
        N Engl J Med. 1995; 333: 11-17
        • Acar J.
        • Iung B.
        • Boissel J.P.
        • et al.
        AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves.
        Circulation. 1996; 94: 2107-2112
        • Hering D.
        • Piper C.
        • Bergemann R.
        • et al.
        Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study.
        Chest. 2005; 127: 53-59
        • Nishimura R.A.
        • Otto C.M.
        • Bonow R.O.
        • et al.
        2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: e57-e185
        • Nishimura R.A.
        • Otto C.M.
        • Bonow R.O.
        • et al.
        2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        Circulation. 2017; 135: e1159-e1195
        • Ahmad Y.
        • Lip G.Y.H.
        • Apostolakis S.
        New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation.
        Expert Rev Cardiovasc Ther. 2012; 10: 1471-1480
        • Chiang C.-E.
        • Naditch-Brûlé L.
        • Murin J.
        • et al.
        Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry.
        Circ Arrhythm Electrophysiol. 2012; 5: 632-639
        • Flaker G.
        • Ezekowitz M.
        • Yusuf S.
        • et al.
        Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
        J Am Coll Cardiol. 2012; 59: 854-855
        • Hohnloser S.H.
        • Duray G.Z.
        • Baber U.
        • et al.
        Prevention of stroke in patients with atrial fibrillation: current strategies and future directions.
        Eur Heart J. 2007; 10: H4-H10
        • Aguilar M.I.
        • Hart R.
        Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.
        Cochrane Database Syst Rev. 2005; : CD001927
        • Hart R.G.
        • Pearce L.A.
        • Aguilar M.I.
        Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.
        Ann Intern Med. 2007; 146: 857-867
        • Winkelmayer W.C.
        • Liu J.
        • Setoguchi S.
        • et al.
        Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation.
        Clin J Am Soc Nephrol. 2011; 6: 2662-2668
        • Bohula E.A.
        • Giugliano R.P.
        • Ruff C.T.
        • et al.
        Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial.
        Circulation. 2016; 134: 24-36
        • Khoury T.
        • Ayman A.R.
        • Cohen J.
        • et al.
        The complex role of anticoagulation in cirrhosis: an updated review of where we are and where we are going.
        Digestion. 2016; 93: 149-159
        • Bonde A.N.
        • Lip G.Y.H.
        • Kamper A.-L.
        • et al.
        Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
        J Am Coll Cardiol. 2014; 64: 2471-2482
        • Siontis K.C.
        • Zhang X.
        • Eckard A.
        • et al.
        Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States.
        Circulation. 2018; 138: 1519-1529
        • Andersson T.
        • Magnuson A.
        • Bryngelsson I.-L.
        • et al.
        Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: a nationwide cohort study of 9519 patients.
        Int J Cardiol. 2014; 177: 91-99
        • Fang M.C.
        • Singer D.E.
        • Chang Y.
        • et al.
        Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study.
        Circulation. 2005; 112: 1687-1691
        • Pancholy S.B.
        • Sharma P.S.
        • Pancholy D.S.
        • et al.
        Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants.
        Am J Cardiol. 2014; 113: 485-490
        • Mikkelsen A.P.
        • Lindhardsen J.
        • Lip G.Y.H.
        • et al.
        Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study.
        J Thromb Haemost. 2012; 10: 1745-1751
        • Wagstaff A.J.
        • Overvad T.F.
        • Lip G.Y.H.
        • et al.
        Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis.
        QJM. 2014; 107: 955-967
        • Hariharan S.
        • Madabushi R.
        Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment.
        J Clin Pharmacol. 2012; 52: 119S-125S
        • Lehr T.
        • Haertter S.
        • Liesenfeld K.-H.
        • et al.
        Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation.
        J Clin Pharmacol. 2012; 52: 1373-1378
        • Connolly S.J.
        • Eikelboom J.
        • Joyner C.
        • et al.
        Apixaban in patients with atrial fibrillation.
        N Engl J Med. 2011; 364: 806-817
        • Eikelboom J.W.
        • Connolly S.J.
        • Brueckmann M.
        • et al.
        Dabigatran versus warfarin in patients with mechanical heart valves.
        N Engl J Med. 2013; 369: 1206-1214
        • Quinn G.R.
        • Severdija O.N.
        • Chang Y.
        • et al.
        Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation.
        Circulation. 2017; 135: 208-219
        • Rivera-Caravaca J.M.
        • Roldán V.
        • Esteve-Pastor M.A.
        • et al.
        Prediction of long-term net clinical outcomes using the TIMI-AF score: comparison with CHA2DS2-VASc and HAS-BLED.
        Am Heart J. 2018; 197: 27-34
        • Fanola C.L.
        • Giugliano R.P.
        • Ruff C.T.
        • et al.
        A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial.
        Eur Heart J. 2017; 38: 888-896
        • Philippart R.
        • Brunet-Bernard A.
        • Clementy N.
        • et al.
        CHA2DS2-VASc score for predicting stroke and thromboembolism in patients with AF and biological valve prosthesis.
        J Am Coll Cardiol. 2016; 67: 343-344
        • Carnicelli A.P.
        • De Caterina R.
        • Halperin J.L.
        • et al.
        Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves.
        Circulation. 2017; 135: 1273-1275
        • Pokorney S.D.
        • Rao M.P.
        • Wojdyla D.M.
        • et al.
        Apixaban use in patients with atrial fibrillation with bioprosthetic valves: insights from ARISTOTLE.
        Circulation. 2015; 132 ([abstract 17277]): A17277
        • Puskas J.
        • Gerdisch M.
        • Nichols D.
        • et al.
        Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial.
        J Thorac Cardiovasc Surg. 2014; 147 (discussion 1210-1): 1202-1210
      1. ELIQUIS (apixaban) [package insert]. Bristol-Myers Squibb Company, Princeton, NJ2012
      2. Savaysa [package insert]. Daiichi Sankyo, Inc., Parsippany, NJ2015
        • Nielsen P.B.
        • Skjøth F.
        • Overvad T.F.
        • et al.
        Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc?.
        Circulation. 2018; 137: 832-840
        • You J.J.
        • Singer D.E.
        • Howard P.A.
        • et al.
        Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e531S-e575
        • U.S. Renal Data System
        2016 USRDS annual data report: epidemiology of kidney disease in the United States.
        National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD2016
        • Sood M.M.
        • Komenda P.
        • Sood A.R.
        • et al.
        The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis?.
        Chest. 2009; 136: 1128-1133
        • Nochaiwong S.
        • Ruengorn C.
        • Awiphan R.
        • et al.
        Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis.
        Open Heart. 2016; 3: e000441
        • Deal E.N.
        • Pope H.
        • Ross W.
        Apixaban use among patients with severe renal impairment.
        Ann Pharmacother. 2014; 48: 1667
        • Stanton B.E.
        • Barasch N.S.
        • Tellor K.B.
        Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment.
        Pharmacotherapy. 2017; 37: 412-419
        • Mavrakanas T.A.
        • Samer C.F.
        • Nessim S.J.
        • et al.
        Apixaban pharmacokinetics at steady state in hemodialysis patients.
        J Am Soc Nephrol. 2017; 28: 2241-2248
        • Reed D.
        • Palkimas S.
        • Hockman R.
        • et al.
        Safety and effectiveness of apixaban compared to warfarin in dialysis patients.
        Res Pract Thromb Haemost. 2018; 2: 291-298
        • Fauchier L.
        • Clementy N.
        • Bisson A.
        • et al.
        Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated?.
        Stroke. 2016; 47: 1831-1836
        • Dias C.
        • Moore K.T.
        • Murphy J.
        • et al.
        Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis.
        Am J Nephrol. 2016; 43: 229-236
        • De Vriese A.S.
        • Caluwé R.
        • Bailleul E.
        • et al.
        Dose-finding study of rivaroxaban in hemodialysis patients.
        Am J Kidney Dis. 2015; 66: 91-98
        • Chan K.E.
        • Edelman E.R.
        • Wenger J.B.
        • et al.
        Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
        Circulation. 2015; 131: 972-979
        • Van de Werf F.
        • Brueckmann M.
        • Connolly S.J.
        • et al.
        A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN).
        Am Heart J. 2012; 163: 931-937.e1
        • Patel M.R.
        • Mahaffey K.W.
        • Garg J.
        • et al.
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Giugliano R.P.
        • Ruff C.T.
        • Braunwald E.
        • et al.
        Edoxaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2013; 369: 2093-2104
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • et al.
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Granger C.B.
        • Alexander J.H.
        • McMurray J.J.V.
        • et al.
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Pan K.-L.
        • Singer D.E.
        • Ovbiagele B.
        • et al.
        Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis.
        J Am Heart Assoc. 2017; 6: e005835
        • Ruff C.T.
        • Giugliano R.P.
        • Braunwald E.
        • et al.
        Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
        Lancet. 2014; 383: 955-962
        • Abraham N.S.
        • Noseworthy P.A.
        • Yao X.
        • et al.
        Gastrointestinal safety of direct oral anticoagulants: a large population-based study.
        Gastroenterology. 2017; 152: 1014-1022.e1
        • Graham D.J.
        • Reichman M.E.
        • Wernecke M.
        • et al.
        Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation.
        JAMA Intern Med. 2016; 176: 1662-1671
        • Larsen T.B.
        • Skjøth F.
        • Nielsen P.B.
        • et al.
        Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
        BMJ. 2016; 353: i3189
        • Lip G.Y.H.
        • Keshishian A.
        • Kamble S.
        • et al.
        Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
        Thromb Haemost. 2016; 116: 975-986
        • Noseworthy P.A.
        • Yao X.
        • Abraham N.S.
        • et al.
        Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation.
        Chest. 2016; 150: 1302-1312
        • Yao X.
        • Abraham N.S.
        • Sangaralingham L.R.
        • et al.
        Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation.
        J Am Heart Assoc. 2016; 5: e003725
        • Ntaios G.
        • Papavasileiou V.
        • Makaritsis K.
        • et al.
        Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis.
        Stroke. 2017; 48: 2494-2503
        • Bai Y.
        • Shi X.-B.
        • Ma C.-S.
        • et al.
        Meta-analysis of effectiveness and safety of oral anticoagulants in atrial fibrillation with focus on apixaban.
        Am J Cardiol. 2017; 120: 1689-1695
        • Calkins H.
        • Willems S.
        • Gerstenfeld E.P.
        • et al.
        Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation.
        N Engl J Med. 2017; 376: 1627-1636
        • Yao X.
        • Tangri N.
        • Gersh B.J.
        • et al.
        Renal outcomes in anticoagulated patients with atrial fibrillation.
        J Am Coll Cardiol. 2017; 70: 2621-2632
        • Lau W.C.Y.
        • Chan E.W.
        • Cheung C.-L.
        • et al.
        Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation.
        JAMA. 2017; 317: 1151-1158
        • Kent A.P.
        • Brueckmann M.
        • Fraessdorf M.
        • et al.
        Concomitant oral anticoagulant and nonsteroidal anti-inflammatory drug therapy in patients with atrial fibrillation.
        J Am Coll Cardiol. 2018; 72: 255-267
        • Douketis J.D.
        • Spyropoulos A.C.
        • Kaatz S.
        • et al.
        Perioperative bridging anticoagulation in patients with atrial fibrillation.
        N Engl J Med. 2015; 373: 823-833
        • Pollack Jr., C.V.
        • Reilly P.A.
        • van Ryn J.
        • et al.
        Idarucizumab for dabigatran reversal - full cohort analysis.
        N Engl J Med. 2017; 377: 431-441
        • Siegal D.M.
        • Curnutte J.T.
        • Connolly S.J.
        • et al.
        Andexanet alfa for the reversal of factor Xa inhibitor activity.
        N Engl J Med. 2015; 373: 2413-2424
        • Connolly S.J.
        • Milling Jr., T.J.
        • Eikelboom J.W.
        • et al.
        Andexanet alfa for acute major bleeding associated with factor Xa inhibitors.
        N Engl J Med. 2016; 375: 1131-1141
        • Reddy V.Y.
        • Sievert H.
        • Halperin J.
        • et al.
        Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.
        JAMA. 2014; 312: 1988-1998
        • Holmes Jr., D.R.
        • Kar S.
        • Price M.J.
        • et al.
        Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
        J Am Coll Cardiol. 2014; 64: 1-12
        • Holmes Jr., D.R.
        • Doshi S.K.
        • Kar S.
        • et al.
        Left atrial appendage closure as an alternative to warfarin for stroke Prevention in atrial fibrillation: a patient-level meta-analysis.
        J Am Coll Cardiol. 2015; 65: 2614-2623
        • Reddy V.Y.
        • Gibson D.N.
        • Kar S.
        • et al.
        Post-approval U.S. experience with left atrial appendage closure for stroke prevention in atrial fibrillation.
        J Am Coll Cardiol. 2017; 69: 253-261
        • Boersma L.V.A.
        • Schmidt B.
        • Betts T.R.
        • et al.
        Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry.
        Eur Heart J. 2016; 37: 2465-2474
        • Reddy V.Y.
        • Möbius-Winkler S.
        • Miller M.A.
        • et al.
        Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology).
        J Am Coll Cardiol. 2013; 61: 2551-2556
        • Boersma L.V.
        • Ince H.
        • Kische S.
        • et al.
        Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial.
        Heart Rhythm. 2017; 14: 1302-1308
        • Holmes D.R.
        • Reddy V.Y.
        • Buchbinder M.
        • et al.
        The assessment of the Watchman device in patients unsuitable for oral anticoagulation (ASAP-TOO) trial.
        Am Heart J. 2017; 189: 68-74
        • Friedman D.J.
        • Piccini J.P.
        • Wang T.
        • et al.
        Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing concomitant cardiac surgery.
        JAMA. 2018; 319: 365-374
        • Melduni R.M.
        • Schaff H.V.
        • Lee H.-C.
        • et al.
        Impact of left atrial appendage closure during cardiac surgery on the occurrence of early postoperative atrial fibrillation, stroke, and mortality: a propensity score-matched analysis of 10 633 patients.
        Circulation. 2017; 135: 366-378
        • Gallagher M.M.
        • Hennessy B.J.
        • Edvardsson N.
        • et al.
        Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion.
        J Am Coll Cardiol. 2002; 40: 926-933
        • Jaber W.A.
        • Prior D.L.
        • Thamilarasan M.
        • et al.
        Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: a transesophageal echocardiographic study.
        Am Heart J. 2000; 140: 150-156
        • You J.J.
        • Singer D.E.
        • Howard P.A.
        • et al.
        Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e531S-e575
        • Nagarakanti R.
        • Ezekowitz M.D.
        • Oldgren J.
        • et al.
        Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
        Circulation. 2011; 123: 131-136
        • Piccini J.P.
        • Stevens S.R.
        • Lokhnygina Y.
        • et al.
        Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
        J Am Coll Cardiol. 2013; 61: 1998-2006
        • Flaker G.
        • Lopes R.D.
        • Al-Khatib S.M.
        • et al.
        Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
        J Am Coll Cardiol. 2014; 63: 1082-1087
        • Cappato R.
        • Ezekowitz M.D.
        • Klein A.L.
        • et al.
        Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.
        Eur Heart J. 2014; 35: 3346-3355
        • Goette A.
        • Merino J.L.
        • Ezekowitz M.D.
        • et al.
        Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
        Lancet. 2016; 388: 1995-2003
        • Pallisgaard J.L.
        • Lindhardt T.B.
        • Hansen M.L.
        • et al.
        Cardioversion and risk of adverse events with dabigatran versus warfarin—a nationwide cohort study.
        PLoS ONE. 2015; 10: e0141377
        • Plitt A.
        • Ezekowitz M.D.
        • De Caterina R.
        • et al.
        Cardioversion of atrial fibrillation in ENGAGE AF-TIMI 48.
        Clin Cardiol. 2016; 39: 345-346
        • Dentali F.
        • Botto G.L.
        • Gianni M.
        • et al.
        Efficacy and safety of direct oral anticoagulants in patients undergoing cardioversion for atrial fibrillation: a systematic review and meta-analysis of the literature.
        Int J Cardiol. 2015; 185: 72-77
        • Ezekowitz M.D.
        • Pollack Jr., C.V.
        • Halperin J.L.
        • et al.
        Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.
        Eur Heart J. 2018; 39: 2959-2971
        • Airaksinen K.E.J.
        • Grönberg T.
        • Nuotio I.
        • et al.
        Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study.
        J Am Coll Cardiol. 2013; 62: 1187-1192
        • Garg A.
        • Khunger M.
        • Seicean S.
        • et al.
        Incidence of thromboembolic complications within 30 days of electrical cardioversion performed within 48 hours of atrial fibrillation onset.
        J Am Coll Cardiol EP. 2016; 2: 487-494
        • Klein A.L.
        • Grimm R.A.
        • Murray R.D.
        • et al.
        Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation.
        N Engl J Med. 2001; 344: 1411-1420
        • von Besser K.
        • Mills A.M.
        Is discharge to home after emergency department cardioversion safe for the treatment of recent-onset atrial fibrillation?.
        Ann Emerg Med. 2011; 58: 517-520
        • Pfizer
        Study of the blood thinner, apixaban, for patients who have an abnormal heart rhythm (atrial fibrillation) and expected to have treatment to put them back into a normal heart rhythm (cardioversion) (EMANATE).
        (Available at:) (Identifier: NCT02100228. Accessed November 22, 2017)
        • Nuotio I.
        • Hartikainen J.E.K.
        • Grönberg T.
        • et al.
        Time to cardioversion for acute atrial fibrillation and thromboembolic complications.
        JAMA. 2014; 312: 647-649
        • Bah A.
        • Nuotio I.
        • Gronberg T.
        • et al.
        Sex, age, and time to cardioversion. Risk factors for cardioversion of acute atrial fibrillation from the FinCV study.
        Ann Med. 2017; 49: 254-259
        • Kleemann T.
        • Becker T.
        • Strauss M.
        • et al.
        Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation < 48 hours undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion.
        J Am Soc Echocardiogr. 2009; 22: 1403-1408
        • Marrouche N.F.
        • Brachmann J.
        • Andresen D.
        • et al.
        Catheter ablation for atrial fibrillation with heart failure.
        N Engl J Med. 2018; 378: 417-427
        • Di Biase L.
        • Mohanty P.
        • Mohanty S.
        • et al.
        Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial.
        Circulation. 2016; 133: 1637-1644
        • Prabhu S.
        • Taylor A.J.
        • Costello B.T.
        • et al.
        Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI Study.
        J Am Coll Cardiol. 2017; 70: 1949-1961
        • Al Halabi S.
        • Qintar M.
        • Hussein A.
        • et al.
        Catheter ablation for atrial fibrillation in heart failure patients: a meta-analysis of randomized controlled trials.
        J Am Coll Cardiol EP. 2015; 1: 200-209
        • Packer D.L.
        • Mark D.B.
        • Robb R.A.
        • et al.
        Catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation (CABANA) trial: study rationale and design.
        Am Heart J. 2018; 199: 192-199
        • Packer D.L.
        • Mark D.B.
        • Robb R.A.
        • et al.
        Catheter ablation vs. antiarrhythmic drug therapy for atrial fibrillation: the results of the Cabana Multicenter International Randomized Clinical Trial.
        Heart Rhythm. 2018; 15 ([abstract B-LBCT01-05]) (940-141)
        • Cannon C.P.
        • Bhatt D.L.
        • Oldgren J.
        • et al.
        Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation.
        N Engl J Med. 2017; 377: 1513-1524
        • Gibson C.M.
        • Mehran R.
        • Bode C.
        • et al.
        Prevention of bleeding in patients with atrial fibrillation undergoing PCI.
        N Engl J Med. 2016; 375: 2423-2434
        • Dewilde W.J.M.
        • Oirbans T.
        • Verheugt F.W.A.
        • et al.
        Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
        Lancet. 2013; 381: 1107-1115
        • Sarafoff N.
        • Martischnig A.
        • Wealer J.
        • et al.
        Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.
        J Am Coll Cardiol. 2013; 61: 2060-2066
        • Jackson L.R.
        • Ju C.
        • Zettler M.
        • et al.
        Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS Study.
        J Am Coll Cardiol Intv. 2015; 8: 1880-1889
        • Lamberts M.
        • Gislason G.H.
        • Olesen J.B.
        • et al.
        Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
        J Am Coll Cardiol. 2013; 62: 981-989
        • Rubboli A.
        • Schlitt A.
        • Kiviniemi T.
        • et al.
        One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry.
        Clin Cardiol. 2014; 37: 357-364
        • Braun O.Ö.
        • Bico B.
        • Chaudhry U.
        • et al.
        Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
        Thromb Res. 2015; 135: 26-30
        • Fiedler K.A.
        • Maeng M.
        • Mehilli J.
        • et al.
        Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE Trial.
        J Am Coll Cardiol. 2015; 65: 1619-1629
        • Koskinas K.C.
        • Räber L.
        • Zanchin T.
        • et al.
        Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary intervention.
        J Am Coll Cardiol Intv. 2016; 9: 1473-1483
        • Crenshaw B.S.
        • Ward S.R.
        • Granger C.B.
        • et al.
        Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
        J Am Coll Cardiol. 1997; 30: 406-413
        • Rathore S.S.
        • Berger A.K.
        • Weinfurt K.P.
        • et al.
        Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes.
        Circulation. 2000; 101: 969-974
        • Goldberg R.J.
        • Seeley D.
        • Becker R.C.
        • et al.
        Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective.
        Am Heart J. 1990; 119: 996-1001
        • Behar S.
        • Zahavi Z.
        • Goldbourt U.
        • et al.
        Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. SPRINT Study Group.
        Eur Heart J. 1992; 13: 45-50
        • Connolly S.J.
        • Pogue J.
        • et al.
        • ACTIVE Investigators
        Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
        N Engl J Med. 2009; 360: 2066-2078
        • You J.J.
        • Singer D.E.
        • Howard P.A.
        • et al.
        Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e531S-e575S
        • Pisters R.
        • Lane D.A.
        • Nieuwlaat R.
        • et al.
        A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
        Chest. 2010; 138: 1093-1100
        • Lopes R.D.
        • Rordorf R.
        • De Ferrari G.M.
        • et al.
        Digoxin and mortality in patients with atrial fibrillation.
        J Am Coll Cardiol. 2018; 71: 1063-1074
        • Vamos M.
        • Erath J.W.
        • Hohnloser S.H.
        Digoxin-associated mortality: a systematic review and meta-analysis of the literature.
        Eur Heart J. 2015; 36: 1831-1838
        • Pedersen O.D.
        • Bagger H.
        • Køber L.
        • et al.
        The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evaluation.
        Eur Heart J. 1999; 20: 748-754
        • McMurray J.
        • Køber L.
        • Robertson M.
        • et al.
        Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial.
        J Am Coll Cardiol. 2005; 45: 525-530
        • Fauchier L.
        • Lecoq C.
        • Ancedy Y.
        • et al.
        Evaluation of 5 prognostic scores for prediction of stroke, thromboembolic and coronary events, all-cause mortality, and major adverse cardiac events in patients with atrial fibrillation and coronary stenting.
        Am J Cardiol. 2016; 118: 700-707
        • Álvarez-Álvarez B.
        • Raposeiras-Roubín S.
        • Abu-Assi E.
        • et al.
        Is 6-month GRACE risk score a useful tool to predict stroke after an acute coronary syndrome?.
        Open Heart. 2014; 1: e000123
        • Bristol-Myers Squibb
        A study of apixaban in patients with atrial fibrillation, not caused by a heart valve problem, who are at risk for thrombosis (blood clots) due to having had a recent coronary event, such as a heart attack or a procedure to open the vessels of the heart.
        (Available at:) (Identifier: NCT02415400. Accessed November 1, 2017)
        • Daiichi Sankyo, Inc.
        Edoxaban treatment versus vitamin K antagonist in patients with atrial fibrillation undergoing percutaneous coronary intervention (ENTRUST-AF-PCI).
        (Available at:) (Identifier: NCT02866175. Accessed November 1, 2017)
        • Boriani G.
        • Glotzer T.V.
        • Santini M.
        • et al.
        Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke prevention Strategies based on Atrial Fibrillation information from implanted devices).
        Eur Heart J. 2014; 35: 508-516
        • Glotzer T.V.
        • Daoud E.G.
        • Wyse D.G.
        • et al.
        The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study.
        Circ Arrhythm Electrophysiol. 2009; 2: 474-480
        • Glotzer T.V.
        • Hellkamp A.S.
        • Zimmerman J.
        • et al.
        Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST).
        Circulation. 2003; 107: 1614-1619
        • Healey J.S.
        • Connolly S.J.
        • Gold M.R.
        • et al.
        Subclinical atrial fibrillation and the risk of stroke.
        N Engl J Med. 2012; 366: 120-129
        • Martin D.T.
        • Bersohn M.M.
        • Waldo A.L.
        • et al.
        Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices.
        Eur Heart J. 2015; 36: 1660-1668
        • Sanna T.
        • Diener H.-C.
        • Passman R.S.
        • et al.
        Cryptogenic stroke and underlying atrial fibrillation.
        N Engl J Med. 2014; 370: 2478-2486
        • Halcox J.P.J.
        • Wareham K.
        • Cardew A.
        • et al.
        Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF Study.
        Circulation. 2017; 136: 1784-1794
        • Bumgarner J.M.
        • Lambert C.T.
        • Hussein A.A.
        • et al.
        Smartwatch algorithm for automated detection of atrial fibrillation.
        J Am Coll Cardiol. 2018; 71: 2381-2388
        • Abed H.S.
        • Wittert G.A.
        • Leong D.P.
        • et al.
        Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial.
        JAMA. 2013; 310: 2050-2060
        • Pathak R.K.
        • Middeldorp M.E.
        • Lau D.H.
        • et al.
        Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study.
        J Am Coll Cardiol. 2014; 64: 2222-2231
        • Pathak R.K.
        • Middeldorp M.E.
        • Meredith M.
        • et al.
        Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY).
        J Am Coll Cardiol. 2015; 65: 2159-2169
        • Abed H.S.
        • Samuel C.S.
        • Lau D.H.
        • et al.
        Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation.
        Heart Rhythm. 2013; 10: 90-100
        • Wang T.J.
        • Parise H.
        • Levy D.
        • et al.
        Obesity and the risk of new-onset atrial fibrillation.
        JAMA. 2004; 292: 2471-2477
        • Wong C.X.
        • Ganesan A.N.
        • Selvanayagam J.B.
        Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions.
        Eur Heart J. 2017; 38: 1294-1302
        • Wong C.X.
        • Abed H.S.
        • Molaee P.
        • et al.
        Pericardial fat is associated with atrial fibrillation severity and ablation outcome.
        J Am Coll Cardiol. 2011; 57: 1745-1751
        • Middeldorp M.E.
        • Pathak R.K.
        • Meredith M.
        • et al.
        PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study.
        Europace. 2018; 20: 1929-1935